FINANCIAL REVIEW
Mesoblast remains an "underperform" recommendation at Macquarie Wealth Management. "In the absence of finding partners to co-develop its products, we envisage significant funding difficultly for MSB in coming years. And given the ongoing trend of big pharma moving away from adult-derived stem-cell therapeutics, we believe finding partners will not be an easy exercise." Price target is $1.33 a share, says Macquarie. In the US, where MESO shares are down about 50 per cent post US relisting, JPMorgan has initiated coverage of Mesoblast (MESO) with an "overweight" rating and December 2016 price target of $US10 (currently trading around $US6).
FINANCIAL REVIEW Mesoblast remains an "underperform"...
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.025(2.17%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.16 | $1.11 | $7.363M | 6.488M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 94863 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 5000 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |